SS-31 vs MOTS-c: Two Mitochondrial Peptides Compared

Bottom Line First

The Short Answer

SS-31 and MOTS-c both target mitochondria but through completely different mechanisms. SS-31 is a structural stabilizer — it binds cardiolipin on the inner mitochondrial membrane and physically organizes the electron transport chain, reducing ROS production at the source. MOTS-c is a mitochondria-derived signaling peptide that activates AMPK, shifts metabolic substrate use, and mimics the systemic effects of exercise. They are complementary rather than competing, and both appear in longevity stacking protocols for this reason.

SS-31 (amino acids)

MOTS-c (amino acids)

~2 hrs

SS-31 half-life

~20 min

MOTS-c half-life

Mechanism Comparison

How They Work Differently

SS-31: Structural Stabilization

SS-31 works inside the mitochondrion by binding cardiolipin — a phospholipid that anchors and organizes the electron transport chain (ETC) complexes. By stabilizing this structure, SS-31 keeps ETC supercomplexes properly organized, reduces electron leak and ROS generation, and maintains ATP output efficiency. It doesn't change cellular signaling; it changes mitochondrial physical organization.

MOTS-c: Metabolic Signaling

MOTS-c is encoded in the mitochondrial genome and is released in response to metabolic stress — including exercise. It circulates systemically and activates AMPK (AMP-activated protein kinase), the master metabolic regulator. This drives a shift from glucose oxidation to fatty acid utilization, increases insulin sensitivity, and triggers transcriptional programs that broadly mimic exercise adaptation. MOTS-c acts more like a hormone than a structural molecule.

Why They Pair Well

SS-31 fixes the engine (ETC structure and ATP efficiency). MOTS-c tells the engine what fuel to burn and how to adapt (substrate switching and metabolic signaling). Operating on different biological layers, they don't compete for the same targets — which is why they're frequently combined in longevity research stacks.

Side by Side

Head-to-Head Comparison

Factor	SS-31	MOTS-c
Origin	Synthetic (engineered)	Mitochondrial genome (endogenous)
Length	4 amino acids	16 amino acids
Primary target	Cardiolipin / IMM	AMPK / metabolic pathways
Mechanism type	Structural / biophysical	Signaling / hormonal
Half-life	~2 hours	~20 minutes
Route	SubQ or IV	SubQ or IV
Research dose	5–10mg/day	5–10mg/day
Key preclinical finding	Reversed mitochondrial aging in aged rats	Exercise-like metabolic effects; lifespan extension in C. elegans
Clinical trials	Phase 2 (HFpEF, AKI)	Phase 1 only
Circulates systemically?	No (stays at mitochondria)	Yes (acts like a hormone)
Primary research interest	Cardiac, renal, muscle aging	Metabolic disease, muscle aging, lifespan

Research Strength

Where Each Has Stronger Evidence

SS-31 Leads On:

Human safety data: Phase 2 trials provide human PK/PD data and a clean safety profile that MOTS-c simply doesn't have yet
Cardiac research: The HFpEF and cardiac surgery AKI programs represent the most advanced clinical work on any mitochondrial peptide
Structural mitochondrial repair: The Siegel (2013) skeletal muscle aging data showing near-full restoration of mitochondrial function is the benchmark for this application

MOTS-c Leads On:

Metabolic effects: Insulin sensitization, fat oxidation, and glucose metabolism data in preclinical models is more extensive for MOTS-c
Exercise mimicry: MOTS-c's AMPK activation and exercise-like transcriptional effects are unique — SS-31 doesn't replicate this
Lifespan extension: C. elegans and some mammalian data on longevity outcomes favors MOTS-c
Systemic effects: Because MOTS-c circulates, it can affect multiple organ systems including brain and adipose tissue — SS-31's effects are more localized to tissues with high mitochondrial demand

Decision Framework

Which Fits Your Research Goals?

Research Goal	Lean Toward	Why
Cardiac / renal protection	SS-31	Direct clinical trial data for these endpoints
Insulin sensitivity / metabolic	MOTS-c	Stronger metabolic signaling data
Age-related muscle decline	Both (stack)	Complementary mechanisms, preclinical data supports both
Exercise performance support	MOTS-c	AMPK activation and exercise-mimicry are MOTS-c specific
ROS / oxidative stress reduction	SS-31	Source-level ROS reduction via ETC stabilization
Longevity / healthspan research	Both (stack)	Mechanistic complementarity; commonly paired
Strongest human safety data	SS-31	Phase 2 trials vs Phase 1 only for MOTS-c

View SS-31 Pricing & Vendor Data

COA-verified vendor pricing with promo codes. Two vendors currently carry SS-31.

View Pricing → Dosage Calculator

Common Questions

FAQ

Can SS-31 and MOTS-c be injected at the same time?

Unlike two GHRH analogs competing for the same receptor, SS-31 and MOTS-c act on entirely different biological targets. There's no known pharmacological reason they can't be co-administered. Most stacking protocols inject them separately (morning and evening, or on alternating days) to keep dosing manageable, not out of concern for interaction.

Which is more expensive?

At typical research doses (5–10mg), costs are comparable. SS-31 usually comes in 50mg vials; MOTS-c in 10mg or 40mg vials. Per-dose cost depends on vendor pricing and vial size. Check current vendor pricing as this changes frequently.

Is there any overlap in mechanism at all?

Both ultimately improve mitochondrial ATP output — SS-31 via structural ETC stabilization, MOTS-c via substrate optimization through AMPK. Both also show anti-inflammatory effects in some models, though via different pathways. The overlap at the endpoint level (better mitochondrial function) is real; the mechanisms getting there are distinct.

Research purposes only. SS-31 (Elamipretide) is a research compound not approved for human use. This content is for educational reference only and does not constitute medical advice.

Keep Reading

SS-31 vs MOTS-c:Two Mitochondrial Peptides Compared